Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? (Q36654923)

15 August 2017

1 reference

title

Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? (English)

1 reference

15 August 2017

Karagiannis TC

1

1 reference

PubMed ID

17109024

15 August 2017

El-Osta A

series ordinal

2

1 reference

15 August 2017

16 November 2006

1 reference

15 August 2017

1 reference

15 August 2017

21

1 reference

15 August 2017

61-65

1 reference

15 August 2017

1

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2404464

15 August 2017

0 references

cites work

Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Acetylation: a regulatory modification to rival phosphorylation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

A review of depsipeptide and other histone deacetylase inhibitors in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Clinical development of histone deacetylase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone deacetylation as a target for radiosensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Modulation of cellular radiation responses by histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Purchase of Aton spotlights HDAC inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

FK228 (depsipeptide): a HDAC inhibitor with pleiotropic antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Class II histone deacetylases: versatile regulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Molecular cloning and characterization of a novel histone deacetylase HDAC10

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Comparative genomics of the class 4 histone deacetylase family indicates a complex evolutionary history

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

The Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Individual histone deacetylases in Drosophila modulate transcription of distinct genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Dissecting the biological functions of Drosophila histone deacetylases by RNA interference and transcriptional profiling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Reduced histone deacetylase in COPD: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Decreased histone deacetylase activity in chronic obstructive pulmonary disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone deacetylase inhibitor-mediated radiosensitization of human cancer cells: class differences and the potential influence of p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Histone deacetylase 4 interacts with 53BP1 to mediate the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Identification of novel isoform-selective inhibitors within class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

DNMT cooperativity--the developing links between methylation, chromatin structure and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Teratogenic effects mediated by inhibition of histone deacetylases: evidence from quantitative structure activity relationships of 20 valproic acid derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Inhibition of histone deacetylase activity on specific embryonic tissues as a new mechanism for teratogenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

7 January 2021

Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

7 January 2021

Cardiotoxicity of histone deacetylase inhibitor depsipeptide in patients with metastatic neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

7 January 2021

Cardiac studies in patients treated with depsipeptide, FK228, in a phase II trial for T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404464

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2404464

1 reference

15 August 2017

1 reference

PubMed ID

17109024